Neurones SA

As of December 31, 2024, Neurones SA carries a market capitalization of 1.06B, placing it among publicly traded companies globally. Its enterprise value stands at 835.57M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Neurones SA's next confirmed earnings release is scheduled for March 10, 2027.

As of December 31, 2024, Neurones SA has 24.27M shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, Neurones SA maintains a current ratio of 2.33, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2024.

As of the close on October 22, 2026, Neurones SA's stock has declined approximately 7.25% over the past 52 weeks. The 50-day moving average sits at 36.70, while the 200-day moving average is 36.86.

As of December 31, 2024, Neurones SA holds 326.49M in cash and equivalents against 42.02M in total debt, resulting in a net debt position of -319.52M. Total book value stands at 378.10M, with working capital of 335.46M providing operational flexibility.